In treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real -world results from the TYSABRI® Observational Program (TOP)

Conference Proceedings

Tim Spelman, Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Heinz Wiendl, Yi Chen, Nolan Campbell, Stephanie Licata, Pei-Ran Ho

NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017

Biogen